Correlative analysis of circulating biomarkers from a phase 1B/2 trial of cabozantinib (C) with or without erlotinib (E) in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC)

作者： Sukhmani K Padda , Yael Rosenberg-Hasson , Joel W Neal , Scott N Gettinger , Jeffrey A Engelman